MDL NUMBER: MFCD00918402
THERAPEUTIC CATEGORY: Flibanserin (code name BIMT-17; proposed trade name Girosa) is a drug that is currently being investigated by Boehringer Ingelheim as a novel, non-hormonal treatment for pre-menopausal women with Hypoactive Sexual Desire Disorder (HSDD). HSDD is the most commonly reported female sexual complaint and characterized by a decrease in sexual desire that causes marked personal distress and/or personal difficulties. According to prevalence studies about 1 in 10 women reported low sexual desire with associated distress, which may be HSDD. The neurobiological pathway of female sexual desire involves interactions among multiple neurotransmitters, sex hormones and various psychosocial factors. Sexual desire is modulated in distinct brain areas by a balance between inhibitory and excitatory neurotransmitters, serotonine acting as an inhibitor while dopamine and norepinephrine act as a stimulator of sexual desire. Flibanserin is a 5-HT1A receptor agonist and 5-HT2A receptor antagonist that had initially been investigated as an antidepressant. Preclinical evidence suggests that flibanserin targets these receptors preferentially in selective brain areas and helps to restore a balance between these inhibitory and excitatory effects. HSDD has been recognized as a distinct sexual function disorder for more than 30 years.
ROTATION BONDS: 2
Chiral Centers: 0
Synonyms: Flibanserin;Bimt 17;3-[2-[4-[4-(Trifluoromethyl)phenyl]piperazin-1-yl]ethyl]-1H-benzimidazol-2-one
Product Categories: Flibanserin Flibanserin
Usage And Synthesis: Flibanserin